# Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

> **NCT05932264** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- NSCLC
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib + Fluzoparib
- **DRUG:** Apatinib + Fluzoparib + Adebrelimab

## Key facts

- **NCT ID:** NCT05932264
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2024-07
- **Final completion:** 2025-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932264, "Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05932264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*